<DOC>
	<DOCNO>NCT01267695</DOCNO>
	<brief_summary>Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Perioperative imatinib mesylate may shrink tumor may reduce chance relapse surgery . This phase II trial study effectiveness perioperative imatinib mesylate treat patient locally advance gastrointestinal stromal tumor .</brief_summary>
	<brief_title>Perioperative Imatinib Mesylate Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description>Open-label trial patient locally advanced GISTs admit Department Surgery , Beijing Cancer Hospital Institute April 2010 May 2013 carry prospectively . Patients plan treated imatinib duration 6 month follow surgical resection . Postoperative imatinib plan administrate 1.5 year . The primary end point recurrent free survival ( RFS ) 2 year ; secondary end point include objective response rate ( ORR ) , surgical outcome drug safety .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Criteria : DISEASE CHARACTERISTICS : Histologically confirm gastrointestinal stromal tumor Locally advance disease : tumour size 〉5 cm mitotic count 〉5/HPF ; tumour size 〉10 cm ; mitotic count 〉10/HPF Potentially resectable disease : Multivisceral resection may necessary get sufficient margin Documented ckit ( CD117 ) expression immunohistochemical analysis either initial core specimen , recurrent disease , original tumor block At least 1 site measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age:18 Performance status : ECOG 03 Life expectancy : Not specify Platelet count &gt; 100,000/mm3 Absolute neutrophil count &gt; 1,500/mm3 Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN hepatic metastasis present ) Bilirubin &lt; 1.5 time ULN No chronic active hepatitis No cirrhosis No chronic liver disease Renal Creatinine &lt; 1.5 time ULN No chronic renal disease Cardiovascular No New York Heart Association class IIIIV cardiac disease No congestive heart failure No myocardial infarction within past 6 month Immunology No active uncontrolled infection No known HIV positivity Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment Must medically fit undergo surgery No primary malignancy within past 5 year except basal cell skin cancer , carcinoma situ cervix , primary malignancy currently clinically significant require active intervention No gastrointestinal obstruction major bleed episode require immediate surgical intervention No uncontrolled diabetes No severe uncontrolled medical disease No significant history noncompliance medical regimen PRIOR CONCURRENT THERAPY : No concurrent anticancer biologic agent More 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) unless disease rapidly progress No concurrent anticancer chemotherapy At least 28 day since prior radiotherapy More 2 week since prior major surgery except tumor biopsy Other At least 28 day since prior investigational drug At least 28 day since prior imatinib mesylate No concurrent therapeutic dos warfarin Concurrent lowmolecular weight heparin minidose warfarin ( 1 mg per day ) prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Gastrointestinal Stromal Tumor</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Perioperative therapy</keyword>
</DOC>